Kallyope
About Kallyope
At Kallyope, we are pioneering the science and understanding of gut and gut-brain biology to create medicines that transform human health. Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Together, we are leveraging a unique combination of leading technologies and a foundation of internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health – from diabetes, obesity, and gut disorders to inflammatory disease, migraine, allergies, and more. For more information, visit www.kallyope.com.
Company Metrics
- Employees: 101-250
- Monthly Visits: 6269
- Tech Stack: 14 active products
Financial Information
- Estimated Revenue: $1M to $10M
- Total Funding: 479000000 USD
- Last Funding: 236000000 USD (Series D)
- Funding Status: Late Stage Venture
Technology Stack
Kallyope actively uses 14 products in their tech stack.
Market Presence
Industries: Biotechnology, Health Care, Medical, Pharmaceutical
Headquarters: New York, New York, United States
Leadership
Employees
- Brett Lauring - Chief Medical Officer (LinkedIn)
- Fernando Salles - Chief Business Officer (LinkedIn)
- Patrick Flanigan - Chief Financial Officer (LinkedIn)
- Shirly Pinto - Chief Scientific Officer (LinkedIn)